# RAPT Therapeutics to implement 1-for-8 reverse stock split

RAPT Therapeutics (RAPT) announced a 1-for-8 reverse stock split effective June 16, 2025, to reduce its outstanding shares from 132.3 million to 16.5 million; the company's stock will trade on a split-adjusted basis starting June 17. The reverse split aims to increase the share price, though the company did not specify reasons for the split in its press release statement. Recent analyst reports show mixed sentiment, with Clear Street and H.C. Wainwright issuing Buy ratings based on the potential of RPT904, while UBS revised its price target to $1.00, citing RAPT's recent in-licensing agreement for RPT904/JYB1904.

Analysis

RAPT Therapeutics (Nasdaq: RAPT) will execute a 1-for-8 reverse stock split effective June 16, 2025, reducing its outstanding common shares from approximately 132.3 million to 16.5 million. While the company did not specify its rationale, such splits are typically employed to increase the per-share trading price, often to meet exchange listing requirements or attract institutional investors, without altering the company's $144 million market capitalization. InvestingPro analysis suggests RAPT, currently trading at $1.09, is undervalued based on its Fair Value metrics. The clinical-stage biopharmaceutical company maintains a robust liquidity position with a current ratio of 21.11 and more cash than debt, reporting approximately $179 million in cash at the end of the first quarter. However, InvestingPro data indicates a rapid cash burn rate. These funds are expected to support operations through the Phase 2b food allergy trial outcomes for its promising anti-IgE antibody, RPT904, with trial initiation planned for the second half of 2025. Analyst sentiment is mixed: Clear Street initiated coverage with a Buy rating and a $3.00 price target, and H.C. Wainwright also assigned a Buy rating with a $6.00 target, both expressing confidence in RPT904. Conversely, UBS revised its price target downwards to $1.00 from $2.00, maintaining a Neutral rating, reflecting the incorporation of RAPT's recent in-licensing agreement for RPT904/JYB1904. The forthcoming clinical data from the RPT904 trial is deemed critical for assessing the drug's potential and defining its addressable market.

Key Decisions for Investors

• Investors should closely monitor RAPT's cash burn rate against its projected runway, especially considering the significant capital requirements for the upcoming Phase 2b trial of RPT904.
• The reverse stock split is a key corporate action to watch, primarily for its impact on share price optics and potential to maintain Nasdaq compliance, rather than an indicator of fundamental value change.
• Given the divergent analyst price targets ($1.00 to $6.00) and the high-stakes nature of the upcoming RPT904 clinical trial data, positions in RAPT should be managed with careful consideration of the binary risk profile inherent in clinical-stage biotechnology investments.